12:00 AM
Jul 20, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MGAWN1: Phase II started

MacroGenics began the double-blind, placebo-controlled, North American Phase II PARADIGM trial to evaluate a single dose of 30 mg/kg intravenous MGAWN1 in about 60 patients with suspected CNS infections due to WNV. In...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >